Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis c-related cirrhosis

被引:150
|
作者
Pekow, Joel R.
Han, Atul K.
Zheng, Hui
Chung, Raymond T.
机构
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA
关键词
hepatitis C virus; hepatocellular carcinoma; hepatc steatosis; cirrhosis;
D O I
10.1002/cncr.22701
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Chronic hepatitis C can result in fatty changes in the liver. Previous studies have suggested that hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection. The authors sought to determine whether hepatic steatosis is associated with hepatocellular carcinoma (HCC) in a cohort of patients with hepatitis C-related cirrhosis. METHODS. The authors retrospectively identified 94 consecutive patients with hepatitis C cirrhosis who underwent liver transplantation from 1992 to 2005 and had pathology available for review. Of these, 32 had evidence of HCC, and 62 had no HCC on explant histology. All explant specimens were graded again for steatosis bV a single, blinded pathologist. Steatosis, age, sex, body mass index, HCV RNA, HCV genotype, Model for End-Stage Liver Disease (MELD) score, chronic alcohol use, and diabetes were examined in univariate and multivariate analyses for association with HCC. RESULTS. In total, 69% of patients in the HCC group and 50% of patients in the control group had evidence of steatosis (1+) on histology. Odds ratios for the development of HCC for each grade of steatosis compared with grade 0 were as follows: grade 1 (1.61 [0.6-4.3]), grade 2 (3.68 (1.1-12.8]), and grade 3 or 4 (8.02 [0.6-108.31) (P =.03 for the trend). In univariate analysis, there was a significant association between increasing steatosis grade (P =.03), older age (56 years vs 49 years; P <.02), higher aspartate aminotransferase (122.5 U/L vs 91.5 U/L; P =.005), higher alanine amino transferase (95.8 U/L vs 57.2 U/L; P =.002), higher alpha- feto protein (113.5 ng/mL vs 17.8 ng/mL; P <.001), lower median HCV RNA (239,000 IU/mL vs 496,500 IU/mL; P =.02), higher biologic MELD score (21.8 vs 20.3; P =.03), and risk of HCC. In multivariate analysis, age (P =.02), AFP (P.007), and steatosis (P =.045) were significantly associated with HCC. CONCLUSIONS. in patients with HCV-related cirrhosis, the presence of hepatic steatosis is independently associated with the development of hepatocellular carcinoma. These findings suggest that steatosis poses an additional risk for HCC and that increased vigilance should be practiced in surveillance of persons with both HCV and steatosis.
引用
收藏
页码:2490 / 2496
页数:7
相关论文
共 50 条
  • [41] Neuropathies in hepatitis C-related liver cirrhosis
    Abdelkader N.A.
    Zaky D.Z.
    Afifi H.
    Saad W.E.
    Shalaby S.I.
    Mansour M.A.
    Indian Journal of Gastroenterology, 2014, 33 (6) : 554 - 559
  • [42] microRNA in Patients with Hepatitis B and Hepatitis C Virus Associated Hepatocellular Carcinoma and Cirrhosis
    Kucukkara, Gokhan
    Aslan, Ferhat Gurkan
    Toka, Bilal
    Koroglu, Mehmet
    Altindis, Mustafa
    VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2019, 25 (03): : 113 - 116
  • [43] Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
    Thomas F. Baumert
    Frank Jühling
    Atsushi Ono
    Yujin Hoshida
    BMC Medicine, 15
  • [44] Rising Incidence of Hepatitis C-related Hepatocellular Carcinoma and Impact of Surveillance
    Shaik, R.
    Gane, E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (07) : 1383 - 1384
  • [45] Hepatitis C-related cirrhosis: Current status
    Conde, Isabel
    Vinaixa, Carmen
    Berenguer, Marina
    MEDICINA CLINICA, 2017, 148 (02): : 78 - 85
  • [46] A cost-effectiveness analysis of screening for hepatocellular carcinoma (HCC) in hepatitis C-related compensated cirrhosis.
    Dube, C
    Nichol, G
    Laupacis, A
    GASTROENTEROLOGY, 1999, 116 (04) : A1204 - A1204
  • [47] De Novo Hepatocellular Carcinoma in Hepatitis C-Related Cirrhosis: Are Advanced Glycation End Products a Key Driver?
    Abdel-Razik, Ahmed
    Shabana, Walaa
    El Nakib, Ahmed Mohamed
    Abdelsalam, Mostafa
    Abdelwahab, Ahmed
    Hasan, Ahmad S.
    Elzehery, Rasha
    Elhelaly, Rania
    Fathy, Aya Ahmed
    Mostafa, Sally Abdallah
    El-Wakeel, Niveen
    Moemen, Dalia
    Eldars, Waleed
    Yassen, Ahmed H.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [48] Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis
    Rincon, Diego
    Lo Iacono, Oreste
    Tejedor, Marta
    Hernando, Ana
    Ripoll, Cristina
    Catalina, Maria-Vega
    Salcedo, Magdalena
    Matilla, Ana
    Senosiain, Maria
    Clemente, Gerardo
    Molinero, Luis-Miguel
    Albillos, Agustin
    Banares, Rafael
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (04) : 487 - 495
  • [49] Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials
    Qu, Li-Shuai
    Chen, Hong
    Kuai, Xiao-Ling
    Xu, Zheng-Fu
    Jin, Fei
    Zhou, Guo-Xiong
    HEPATOLOGY RESEARCH, 2012, 42 (08) : 782 - 789
  • [50] Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection
    Ohata, K
    Hamasaki, K
    Toriyama, K
    Matsumoto, K
    Saeki, A
    Yanagi, K
    Abiru, S
    Nakagawa, Y
    Shigeno, M
    Miyazoe, S
    Ichikawa, T
    Ishikawa, H
    Nakao, K
    Eguchi, K
    CANCER, 2003, 97 (12) : 3036 - 3043